Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
- Tuesday, September 15, 2020, 7:29
- Environment
- Add a comment
NEW YORK, Sept. 15, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed…
About the Author
adminasapcorp has written 41755 stories on this site.